AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms OSCAR1
- Sponsors Roche
- 13 Sep 2018 Status changed from active, no longer recruiting to completed.
- 10 May 2018 Planned End Date changed from 1 Aug 2017 to 30 Jun 2018.
- 10 May 2018 Planned primary completion date changed from 1 Aug 2017 to 30 Jun 2018.